Details for New Drug Application (NDA): 211829
✉ Email this page to a colleague
The generic ingredient in RANOLAZINE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
Summary for 211829
Tradename: | RANOLAZINE |
Applicant: | Sciegen Pharms Inc |
Ingredient: | ranolazine |
Patents: | 0 |
Suppliers and Packaging for NDA: 211829
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 211829 | ANDA | ScieGen Pharmaceuticals, Inc | 50228-423 | 50228-423-05 | 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-423-05) |
RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 211829 | ANDA | ScieGen Pharmaceuticals, Inc | 50228-423 | 50228-423-30 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-423-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG | ||||
Approval Date: | Jun 4, 2019 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
Approval Date: | Jun 4, 2019 | TE: | AB | RLD: | No |
Complete Access Available with Subscription